Femtech describes a category. Women’s health describes a life

By Ema founder and CEO, Amanda Ducach

Ema’s claim to fame is that “she” was the first agentic AI for women’s health.

That means that as the CEO, I get to spend my days speaking with women’s health founders and funders about AI for women.  And… I have noticed something that I wanted to share.

There’s a growing confusion in the market: “femtech” and “women’s health” are often used interchangeably. But while they’re deeply connected, they’re not the same.

All femtech is women’s health. But not all women’s health is femtech. Both matter. But the distinction matters, too.

Femtech: A Catalyst for Innovation, Not a Catch-All

Coined in 2016 by Clue founder Ida Tin, femtech provided a language for a long-overlooked corner of healthcare and has since become one of the fastest-growing verticals in digital health.

Femtech:

• Names a market that was previously invisible.
• Unlocks funding, innovation, and legitimacy.
• Centers historically neglected needs in health tech.

Today, femtech includes everything from fertility and contraception to menopause care, pelvic health, sexual wellness, mental health, and cancer screening.

It’s a category with momentum and one that is expanding.

But categories have limits. When we frame the full breadth of women’s health needs solely through the lens of femtech, we risk both narrowing the scope and limiting its impact.

That’s not a failure of the category. It’s a signal that we must build beyond it.

Women’s Health: Bigger Than a Market. More Complex Than a Milestone

Women’s health is a lifelong, whole-body experience.

            Amanda Ducach

It spans:

• Cardiovascular, metabolic, neurological, and autoimmune conditions
• Mental health across life stages
• Hormonal transitions beyond reproduction (e.g., perimenopause, PCOS)
• The interplay of biology, identity, stress, and systemic bias

And yet, women remain underdiagnosed, undertreated, and underserved, partly because mainstream healthcare systems still don’t reflect their reality.

Women’s health encompasses more than just gynaecology. It’s a biopsychosocial model of care that sees women in full, not just in episodes.

Why the Distinction Matters

Femtech is growing, but funding remains concentrated in specific stages, including fertility, pregnancy, and postpartum. These are deeply important, but they’re just a fraction of the health journey.

Most of women’s health happens outside of reproduction.
Think: PMDD in adolescence, anxiety in early adulthood, migraines and autoimmune flare-ups, perimenopause in midlife, and heart disease risk post-menopause.

When investment flows into what’s easiest to monetise in the short term, we risk reinforcing a narrow story of what women need and when.

The result? Gaps in care, missed opportunities, and underserved lives. The risk isn’t that femtech is too small. It’s that we treat women’s health as if it is.

Femtech as a Bridge, Not a Box

The future isn’t about picking sides. It’s about connecting categories with complexity.

Femtech is an essential bridge: from invisibility to visibility, from stigma to innovation. But it’s not the endpoint. To meet women where they actually are, we must:

• Design for the whole hormonal arc, not just milestones.
• Expand data models to reflect lived experience across race, gender identity, and life stage.
• Invest in long-term conditions, not just urgent ones.
• Prioritise prevention, quality of life, and self-trust, not just outcomes that are easily measurable.

As the Health Innovation Network warns, without this evolution, even well-intentioned femtech could inadvertently widen the health equity gap.

The Bottom Line

Femtech is a powerful industry. Women’s health is a lifelong mission.

All femtech is women’s health. But not all women’s health is femtech.

Recognising that is how we build products and care systems that actually fit women’s lives.

Find out more about Ema at emaapp.co